The company partners with Janssen, Roche, and Sanofi to develop novel immunomodulators, with a clinical stage program focused on VISTA, a checkpoint regulator, and pre-clinical programs targeting antibodies that target novel immuno-metabolic proteins. ImmuNext's therapeutics technology modulates the immune system to treat cancer and autoimmune diseases, conducting biotechnology research and experimental development for genetically-altered products that can be used by various industries.